Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

The Cytogenetic and Molecular Testing Landscape in Patients with Newly Diagnosed Acute Myeloid Leukemia in Routine Clinical Practices in the United States

Kimo Bachiashvili, Shuko Harada, Esprit Ma, Achal Patel, Rongrong Wang, Archibong Yellow-Duke, Melissa Montez, Vivek Chopra, Cat N. Bui, Pankit Vachhani

Blood (2023) 142 (Supplement 1): 2436.

https://doi.org/10.1182/blood-2023-179370

Published: 2023

Journal Articles

Treatment Outcomes of Stem Cell Transplant in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents: Experience from Routine Clinical Practices in the United States

Kimo Bachiashvili, Esprit Ma, Achal Patel, Rongrong Wang, Archibong Yellow-Duke, Melissa Montez, Cat N. Bui, Sarah Worth, Pankit Vachhani

Blood (2023) 142 (Supplement 1): 7415.

https://doi.org/10.1182/blood-2023-178008

Published: 2023

Journal Articles

Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Blood (2023) 142 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2023-173283

Published: 2023

Journal Articles

Unmet Medical Needs Amongst Older Patients Aged ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy: Experience from a Predominately United States Community Setting

Tapan M. Kadia, Alex Bataller, Esprit Ma, Achal Patel, Rongrong Wang, Archibong Yellow-Duke, Melissa Montez, Cat N. Bui, Farhad Ravandi

Blood (2023) 142 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2023-178004

Published: 2023

Journal Articles

Real-World Treatment Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed Acute Myeloid Leukemia: Updated Experience from a Predominately Community Setting in the US

Pankit Vachhani, Esprit Ma, Tao Xu, Melissa Montez, Sarah Worth, Wei-Han Cheng, Michael Werner, Jonathan Abbas, William Donnellan

Blood (2022) 140 (Supplement 1): 683–684.

https://doi.org/10.1182/blood-2022-157509

Published: 2022

Journal Articles

Burden of Illness in Patients with Higher-Risk Myelodysplastic Syndromes By Baseline Transfusion Status

Amer M. Zeidan, Carmen Ng, Archibong Yellow-Duke, Neil Lamarre, Wei-Han Cheng, Esprit Ma

Blood (2022) 140 (Supplement 1): 11032–11034.

https://doi.org/10.1182/blood-2022-157666

Published: 2022

Journal Articles

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Blood (2022) 140 (Supplement 1): 11026–11028.

https://doi.org/10.1182/blood-2022-159615

Published: 2022

Journal Articles

Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative

Blood (2021) 138 (Supplement 1): 1271.

https://doi.org/10.1182/blood-2021-151586

Published: 2021

Journal Articles

Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative

Blood (2021) 138 (Supplement 1): 2328.

https://doi.org/10.1182/blood-2021-151285

Published: 2021

Journal Articles

Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States

Pankit Vachhani, Jonathan A. Abbas, Evelyn M. Flahavan, Esprit Ma, Tao Xu, Huan Jin, Melissa Montez, Weize Huang, Anda Gershon, Grace Ku, Brannon Flores, Maika Onishi, Cat N. Bui, William Donnellan

Blood (2021) 138 (Supplement 1): 2290.

https://doi.org/10.1182/blood-2021-147851

Published: 2021

Journal Articles

Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective

Keith W. Pratz, Xinglei Chai, Jipan Xie, Lei Yin, Xiaoyu Nie, Melissa Montez, Erica Iantuono, Lisa Downs, Esprit Ma

Blood (2021) 138 (Supplement 1): 112.

https://doi.org/10.1182/blood-2021-148338

Published: 2021

Journal Articles

Treatment Patterns and Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMA) in the United States (US)

Timothy S. Pardee, MDPhD, Jessica Oschwald, Esprit Ma, Tao Xu, Melissa Montez, Giridharan Ramsingh, Wan-Jen Hong, MD, Michelle Choi, Evelyn M. Flahavan

Blood (2020) 136 (Supplement 1): 14–16.

https://doi.org/10.1182/blood-2020-134830

Published: 2020

Journal Articles

Use of Venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) - Real World (RW) Response, Treatment Duration, Dose and Schedule Modifications

William Donnellan, MD, Tao Xu, Esprit Ma, Huan Jin, Melissa Montez, Michelle Choi, Grace Ku, Raj Anand Rajeswaran, Giridharan Ramsingh, Evelyn M. Flahavan

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-134820

Published: 2020

Journal Articles

Treatment Patterns and Outcomes of Multiple Myeloma (MM) with Chromosome Translocation (11;14) in United States (US) Routine Clinical Practice

Shebli Atrash, MD, Evelyn M. Flahavan, Tao Xu, Esprit Ma, Sudeep Karve, Wan-Jen Hong, MD, Gilbert Jirau-Lucca, Michael Nixon, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 40–43.

https://doi.org/10.1182/blood-2020-134703

Published: 2020

Journal Articles

Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-134789

Published: 2020

Journal Articles

Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone

Cristina Gasparetto, MD, Rakesh Popat, Shaji K. Kumar, MD, Michele Cavo, Javier de la Rubia, MD PhD, Vania T.M. Hungria, MD PhD, Hans Salwender, Kenshi Suzuki, MD PhD, Inho Kim, MD PhD, James Maciel, Liang-Tsai Hsiao, Philippe Moreau, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Jia Jia, PhD MBA, Sudeep Karve, PhD, Esprit Ma, Jacob Devine, MA, Katy Benjamin

Blood (2019) 134 (Supplement_1): 3177.

https://doi.org/10.1182/blood-2019-127387

Published: 2019

Journal Articles

Development of a Concept-Driven Disease Impact Instrument from Patients with Hemophilia (Pediatric and Adult) and Caregivers

Jessica T. Markowitz, Esprit Ma, Paul Solari, Patrick Marquis, Amy D. Shapiro, MD, Barbara Konkle, MD, Peter Trask, Edmund Pezalla, Anna Christian, Michelle Rice, Wendy E. Owens, MA, Kimberly Haugstad, Yaping Xu, Richard H. Ko, Jennifer Whiteley, Robert F. Sidonio

Blood (2017) 130 (Supplement 1): 4732.

https://doi.org/10.1182/blood.V130.Suppl_1.4732.4732

Published: 2017

Journal Articles

Comparative Effectiveness Research on the Treatment Outcomes of Subcutaneous (SC) and Intravenous (IV) Bortezomib (BTZ) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

Robert M. Rifkin, Esprit Ma, MPH, Robyn Harrell, MS, Yanyan Zhu, PhD MPH, Edward Dow, MD, Liviu Niculescu, MDPhD, Vijayveer Bonthapally, PhD

Blood (2015) 126 (23): 4506.

https://doi.org/10.1182/blood.V126.23.4506.4506

Published: 2015

Journal Articles

Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices

Alan P Skarbnik, MD, Esprit Ma, MPH, Marie-Hélène Lafeuille, MA, Jonathan Fortier, MA, Tatyana Feldman, MD, Mei Sheng Duh, MPH, ScD, Yvette Ng, MS, MBA, Helgi van de Velde, MD PhD, Edward Dow, MD, Liviu Niculescu, MD, Vijayveer Bonthapally, PhD, Andre Goy, MD MS

Blood (2014) 124 (21): 1740.

https://doi.org/10.1182/blood.V124.21.1740.1740

Published: 2014

Journal Articles

Impact Of Route Of Bortezomib (B) Administration On Dose Intensity and Time To Dose Reduction In Previously Untreated Patients (Pts) With Multiple Myeloma (MM)

Robert M Rifkin, MD, FACP, Clara Chen, MS, Rahul Dhanda, Ph.D, Debra Rembert, RN, MSN, NP, Abbie Ba-Mancini, BS MBA, Esprit Ma, MPH, Yanyan Zhu, Ph.D, MPH, Edward Dow, MD, Liviu Niculescu, MD

Blood (2013) 122 (21): 1941.

https://doi.org/10.1182/blood.V122.21.1941.1941

Published: 2013

NARROW

The Cytogenetic and Molecular Testing Landscape in Patients with Newly Diagnosed Acute Myeloid Leukemia in Routine Clinical Practices in the United States

Treatment Outcomes of Stem Cell Transplant in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents: Experience from Routine Clinical Practices in the United States

Unmet Medical Needs Amongst Older Patients Aged ≥60 Years with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy: Experience from a Predominately United States Community Setting

Real-World Treatment Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed Acute Myeloid Leukemia: Updated Experience from a Predominately Community Setting in the US

Burden of Illness in Patients with Higher-Risk Myelodysplastic Syndromes By Baseline Transfusion Status

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative

Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative

Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States

Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective

Treatment Patterns and Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Hypomethylating Agents (HMA) in the United States (US)

Use of Venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) - Real World (RW) Response, Treatment Duration, Dose and Schedule Modifications

Treatment Patterns and Outcomes of Multiple Myeloma (MM) with Chromosome Translocation (11;14) in United States (US) Routine Clinical Practice

Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone

Development of a Concept-Driven Disease Impact Instrument from Patients with Hemophilia (Pediatric and Adult) and Caregivers

Comparative Effectiveness Research on the Treatment Outcomes of Subcutaneous (SC) and Intravenous (IV) Bortezomib (BTZ) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices

Impact Of Route Of Bortezomib (B) Administration On Dose Intensity and Time To Dose Reduction In Previously Untreated Patients (Pts) With Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only